Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.

[1]  H. Ghofrani,et al.  Relationship Between Time From Diagnosis and Morbidity or Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study. , 2021, Chest.

[2]  V. Cottin,et al.  Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension , 2020, European Respiratory Journal.

[3]  R. Naeije,et al.  Risk reduction and right heart reverse remodeling by upfront triple combination therapy in pulmonary arterial hypertension. , 2020, Chest.

[4]  V. McLaughlin,et al.  Macitentan in pulmonary hypertension (PH): Data from OPUS and OrPHeUS real-world data sets , 2019, Pulmonary hypertension.

[5]  Z. Jing,et al.  Risk stratification and medical therapy of pulmonary arterial hypertension , 2019, European Respiratory Journal.

[6]  M. Humbert,et al.  Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives , 2019, European Respiratory Journal.

[7]  H. Ghofrani,et al.  Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study , 2018, American Journal of Cardiovascular Drugs.

[8]  M. Humbert,et al.  Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled , 2017, European Respiratory Review.

[9]  Simon Gibbs,et al.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension , 2015, European Respiratory Journal.

[10]  J. Barberà,et al.  Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. , 2015, The New England journal of medicine.

[11]  H. Ghofrani,et al.  Selexipag for the Treatment of Pulmonary Arterial Hypertension. , 2014, The New England journal of medicine.

[12]  M. Humbert,et al.  Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study , 2014, European Respiratory Journal.

[13]  Z. Jing,et al.  Macitentan and morbidity and mortality in pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[14]  A. Torbicki,et al.  Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension , 2012, European Respiratory Journal.

[15]  B. Brundage,et al.  Tadalafil Therapy for Pulmonary Arterial Hypertension , 2009, Circulation.

[16]  J. Tijssen,et al.  Beta blockers in heart failure haemodynamics, clinical effects and modes of action. , 2001, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

[17]  Australia..  Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease , 1997, The Lancet.